TrialThe Lancet. Oncology2016

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

F Stephen Hodi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.